CStone initiates a bridging Phase I clinical trial for PD-1 antibody CS1003 with first patient dosed in China |
| November 19, 2018 | November 2018 Bond Updates |
|
SUZHOU, China, Nov. 19, 2018 /PRNewswire/ -- CStone Pharmaceuticals (CStone) today announced that a first patient has been enrolled and dosed in a Phase I clinical trial in China for the recombinant humanized anti-programmed death-1 (PD-1) monoclonal antibody (mAb) CS1003. This... |
| View more at: https://www.prnewswire.com:443/news-releases/cstone-initiates-a-bridging-phase-i-clinical-trial-for-pd-1-antibody-cs1003-with-first-patient-dosed-in-china-300752680.html |
| Related News |
|